Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DME HOME
NCT06610747Recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Randomised, open-label trial in diabetic macular edema (DME) (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Best-Corrected Visual Acuity at 96 weeks. Started Oct 2024; status: recruiting.
02
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06610747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610747.